Published in Clin Vaccine Immunol on August 19, 2009
High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol (2010) 1.05
Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol (2011) 1.00
Thymopoietic and bone marrow response to murine Pneumocystis pneumonia. Infect Immun (2011) 0.87
Serum (1->3)-beta-D-glucan levels in primary infection and pulmonary colonization with Pneumocystis jirovecii. J Clin Microbiol (2011) 0.83
Serum (1->3)-{beta}-D-Glucan assay for the diagnosis of Pneumocystis jiroveci pneumonia. Clin Vaccine Immunol (2010) 0.75
Elevated serum beta-D-glucan levels in immunocompromised children with clinical suspicion for Pneumocystis jirovecii pneumonia. Clin Vaccine Immunol (2011) 0.75
Pneumocystis pneumonia during Postoperative Adjuvant Chemotherapy for Breast Cancer. Case Rep Oncol Med (2013) 0.75
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep (1992) 22.29
Pneumocystis pneumonia. N Engl J Med (2004) 5.86
Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis (2005) 5.24
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis (2008) 3.19
Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol (2005) 2.38
Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol (2005) 2.22
Contribution of the (1-->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol (2007) 1.53
Reappraisal of the serum (1-->3)-beta-D-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years. Clin Infect Dis (2008) 1.50
Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis (2008) 1.43
(1->3)beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med (2007) 1.27
Reactivity of (1-->3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother (2006) 1.22
Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med (2009) 1.12
Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis (2009) 1.01
Detection of Pneumocystis jirovecii by two staining methods and two quantitative PCR assays. Infection (2008) 0.98
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis (2013) 4.06
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis (2006) 1.89
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One (2011) 1.73
A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis (2007) 1.68
Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer (2005) 1.66
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica (2013) 1.26
Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J (2006) 1.25
Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant (2009) 1.25
Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) (2009) 1.24
Ocular manifestations of candidemia. Clin Infect Dis (2011) 1.22
Novel beta-lactam antibiotics and inhibitor combinations. Expert Opin Investig Drugs (2008) 1.21
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther (2003) 1.19
A case of secondary syphilis presenting as optic neuritis. Neurol Sci (2010) 1.17
Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis (2007) 1.17
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care (2010) 1.17
A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer (2010) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
(1-3)-β-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. Clin Infect Dis (2013) 1.09
Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica (2004) 1.08
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol (2010) 1.06
Latent tuberculosis infection and associated risk factors among undergraduate healthcare students in Italy: a cross-sectional study. BMC Infect Dis (2013) 1.06
High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol (2010) 1.05
Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis (2010) 1.02
Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis (2009) 1.02
Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect (2012) 1.02
Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol (2007) 1.01
Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol (2011) 1.00
Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother (2009) 1.00
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica (2013) 0.99
High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents (2010) 0.98
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res (2011) 0.97
The l1-l2 regularization framework unmasks the hypoxia signature hidden in the transcriptome of a set of heterogeneous neuroblastoma cell lines. BMC Genomics (2009) 0.97
A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J (2003) 0.96
Voriconazole in clinical practice. J Chemother (2012) 0.96
Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis (2003) 0.96
Galactomannan testing might be useful for early diagnosis of fusariosis. Diagn Microbiol Infect Dis (2012) 0.96
Occurrence, presentation and treatment of candidemia. Expert Rev Clin Immunol (2012) 0.96
Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis. Clin Infect Dis (2013) 0.95
Combination therapy for invasive aspergillosis. Clin Infect Dis (2004) 0.95
Current status of newer carbapenems. Curr Med Chem (2009) 0.95
Conditions associated with infections of indwelling central venous catheters in cancer patients: a summary. Br J Haematol (2003) 0.95
The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients. Curr HIV Res (2013) 0.90
Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Crit Care (2010) 0.90
Epidemiology and risk factors for bloodstream infections after allogeneic hematopoietic stem cell transplantion. New Microbiol (2007) 0.90
Galactomannan in piperacillin-tazobactam: how much and to what extent? Antimicrob Agents Chemother (2005) 0.89
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J Antimicrob Chemother (2006) 0.88
Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo. J Antimicrob Chemother (2013) 0.88
A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis (2004) 0.88
Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy? Curr Med Chem (2008) 0.88
Long course of daptomycin in the treatment of meticillin-resistant Staphylococcus epidermidis endocarditis and spondylodiscitis. Int J Antimicrob Agents (2009) 0.87
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. AIDS Care (2011) 0.86
Bordetella holmesii endocarditis in a patient with systemic lupus erythematous treated with immunosuppressive agents. J Chemother (2012) 0.84
Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients. Hum Vaccin Immunother (2014) 0.84
Invasive aspergillosis: diagnosis, prophylaxis and treatment. Curr Opin Hematol (2008) 0.84
Identification of a New Delhi metallo-β-lactamase-4 (NDM-4)-producing Escherichia coli in Italy. BMC Microbiol (2014) 0.84
Adherence to international and national recommendations for the prevention of surgical site infections in Italy: results from an observational prospective study in elective surgery. Am J Infect Control (2012) 0.83
Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol (2006) 0.83
Bacterial infections in hematopoietic stem cell transplantation recipients. Curr Opin Hematol (2014) 0.83
Invasive candidiasis in non-hematological patients. Mediterr J Hematol Infect Dis (2011) 0.83
Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. J Chemother (2013) 0.82
Measles outbreak in adults in Italy. Infez Med (2011) 0.82
Transitioning HIV-infected children and adolescents into adult care: an Italian real-life experience. J Assoc Nurses AIDS Care (2015) 0.81
Identification of multiple hypoxia signatures in neuroblastoma cell lines by l1-l2 regularization and data reduction. J Biomed Biotechnol (2010) 0.81
Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. J Med Case Rep (2009) 0.81
Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. J Antimicrob Chemother (2009) 0.81
Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry. BMC Infect Dis (2010) 0.81
Managing invasive fungal infections: relying on clinical instincts or on a rational navigation system? J Antimicrob Chemother (2011) 0.81
Current role of echinocandins in the management of invasive aspergillosis. Curr Infect Dis Rep (2011) 0.80
Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother (2007) 0.80
Case report of the reliability 1,3-β-D-glucan monitoring during treatment of peritoneal candidiasis in a child receiving continuous peritoneal dialysis. Clin Vaccine Immunol (2012) 0.80
[First case report of catheter-related fungemia by Candida nivariensis in the Iberian Peninsula]. Rev Iberoam Micol (2012) 0.80
HIV serological screening in a population of pregnant women in the Republic of Congo: suitability of different assays. Trop Med Int Health (2008) 0.80
Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev Anti Infect Ther (2006) 0.80
Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae. Am J Infect Control (2012) 0.80
Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs. AIDS Patient Care STDS (2008) 0.80
CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus. Biol Blood Marrow Transplant (2011) 0.80
Enterococcal bloodstream infection after hematopoietic stem cell transplant: experience of a center with a low prevalence of vancomycin-resistant enterococci. Clin Infect Dis (2012) 0.79
Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents. AIDS (2012) 0.79
Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. Mycoses (2015) 0.79
Evaluation of antigen-specific T-cell responses with a miniaturized and automated method. Clin Vaccine Immunol (2008) 0.79
HIV and accelerated atheroprogression: role of antiretroviral therapy. Curr Pharm Biotechnol (2012) 0.79
Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on. Expert Opin Emerg Drugs (2013) 0.79
Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis. Clin Infect Dis (2003) 0.78
Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. Clin Infect Dis (2003) 0.78
Non-cultural methods for the diagnosis of invasive fungal disease. Expert Rev Anti Infect Ther (2014) 0.78